Dragan Grabulovski
Algemeen Directeur bij Araris Biotech AG
Profiel
Dragan Grabulovski was the founder of Covagen AG, a company founded in 2007 where he held the title of Wissenschaftler from 2007 to 2009.
He is also the founder of Araris Biotech AG, a company founded in 2019 where he currently holds the titles of Chairman & Chief Executive Officer.
In addition to his founding positions, Dr. Grabulovski currently holds the position of Director, Head-Business Development & Strategy at Memo Therapeutics AG.
He also serves as a Venture Partner at Pureos Partners AG since 2021.
Dr. Grabulovski's education includes undergraduate and doctorate degrees from the Swiss Federal Institute of Technology.
Actieve functies van Dragan Grabulovski
| Bedrijven | Functie | Begin |
|---|---|---|
Araris Biotech AG
 Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | Algemeen Directeur | 04-10-2023 |
Memo Therapeutics AG
 Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Directeur/Bestuurslid | - |
Pureos Partners AG
 Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Private Equity Investor | 01-09-2021 |
Eerdere bekende functies van Dragan Grabulovski
| Bedrijven | Functie | Einde |
|---|---|---|
Covagen AG
 Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Oprichter | - |
Opleiding van Dragan Grabulovski
| Swiss Federal Institute of Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 4 |
|---|---|
Covagen AG
Covagen AG BiotechnologyHealth Technology Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland. | Health Technology |
Memo Therapeutics AG
Memo Therapeutics AG BiotechnologyHealth Technology Memo Therapeutics AG develops recombinant immunoglobulins and human-derived monoclonal antibodies. Its products include human antibodies, human immune repertoire analysis, classic antibody discovery and pipeline. The company was founded by Christoph Esslinger on November 29, 2012 and is headquartered in Basel, Switzerland. | Health Technology |
Pureos Partners AG
Pureos Partners AG Investment ManagersFinance Pureos Partners AG (Pureos Partners) is a venture capital division of Bellevue Asset Management AG founded in 2017. The firm is headquartered in Zurich, Switzerland. | Finance |
Araris Biotech AG
Araris Biotech AG Miscellaneous Commercial ServicesCommercial Services Araris Biotech AG engages in the development and research of an antibody-drug conjugate (ADC) linker technology. It focuses on the production of ADCs. Its linker platform enables the attachment of payload to off the shelf antibodies without the need of antibody engineering. The company was founded by Philipp Spycher, Isabella Attinger-Toller, and Dragan Grabulovski and is headquartered in Z?rich, Switzerland. | Commercial Services |
